Compare Inovio Pharmaceuticals Inc (INO) vs Match Group Inc (MTCH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Match Group Inc — how do they compare? Inovio Pharmaceuticals Inc trades at $1.1 (market cap $112.19M), while Match Group Inc trades at $41.48 (market cap $9.53B). The key difference: Match Group Inc is far larger — about 84.9× Inovio Pharmaceuticals Inc's market cap, and Match Group Inc pays a 1.93% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and Match Group Inc for 115 Days on average.
| INO | MTCH | |
|---|---|---|
Market Cap | $112.19M | $9.53B |
Volume | 3,201,278 | 3,228,794 |
Sector | Health | Media |
52-Week High | $2.65 | $44.40 |
52-Week Low | $0.66 | $28.90 |
Typical Hold Time | 43 Days | 115 Days |
Enterprise Value | $83.51M | $12.49B |
Dividend Yield | — | 1.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Inovio Pharmaceuticals trades at $1.155, up 2.21% today, with a bearish technical signal despite recent earnings beats. The company faces significant fundamental challenges with minimal revenue of $65,340 and substantial losses, reflected in a -130,000% net margin. Key catalyst is the October 30, 2026 FDA decision on INO-3107 for recurrent respiratory papillomatosis, with analyst consensus leaning bullish at a $2.75 price target.
Investment outlook hinges on FDA approval success; upside exists if INO-3107 gains approval, but persistent cash burn and lack of commercial revenue pose substantial risks. The stock remains speculative with high volatility expected around regulatory milestones.
MTCH trades at $40.86, up 0.59% on the day, with a bullish technical signal and strong analyst consensus. The stock shows robust fundamentals with a P/E of 14.71, net income margin of 20.17%, and consistent cash flow generation. Recent earnings beat expectations in Q2 2026, and positive news highlights product innovation and growth in Hinge.
The outlook is positive, supported by margin expansion and strategic initiatives, but risks include high debt levels and competitive pressures. Wall Street sentiment is bullish with a $42.29 price target, offering modest upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Match Group Inc
Match Group is a provider of online dating products. The firm became public in 2015 and was more than 80% owned by IAC/InterActiveCorp until IAC spun it off in the second quarter of 2020. The company has a vast portfolio of different online dating service providers, including Tinder, Match.com, OkCupid, Plenty of Fish, and Meetic. Match Group has more than 45 brands of online dating sites and/or apps, from which it generates user fee revenue (95%) and advertising revenue (5%).
Read more on MTCH →
